Nutriband (NTRB) 10-Q 15 Dec 20 2021 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Oct. 31, 2020	Dec. 15, 2020
Document Information Line Items
Entity Registrant Name	NutriBand Inc.
Document Type	10-Q
Current Fiscal Year End Date	--01-31
Entity Common Stock, Shares Outstanding		6,126,447
Amendment Flag	false
Entity Central Index Key	0001676047
Entity Current Reporting Status	Yes
Entity Filer Category	Non-accelerated Filer
Document Period End Date	Oct. 31, 2020
Document Fiscal Year Focus	2021
Document Fiscal Period Focus	Q3
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Shell Company	false
Entity Ex Transition Period	false
Entity File Number	000-55654
Entity Incorporation, State or Country Code	NV
Entity Interactive Data Current	No

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Oct. 31, 2020	Jan. 31, 2020
CURRENT ASSETS:
Cash and cash equivalents	$ 193,392	$ 10,181
Accounts receivable	90,660	12,833
Inventory	39,209
Prepaid expenses		20,167
Total Current Assets	323,261	43,181
PROPERTY & EQUIPMENT-net	1,282,440	111,029
OTHER ASSETS:
Goodwill	8,187,196	1,719,235
Right of use asset-net		9,610
Intangible assets-net	286,898	314,700
Total Non Current Assets	9,756,534	2,154,574
TOTAL ASSETS	10,079,795	2,197,755
CURRENT LIABILITIES:
Accounts payable and accrued expenses	811,775	771,931
Derivative liability		928,774
Operating lease liability		10,050
Deferred revenue	118,017
Notes payable-related party	1,500,000	29,067
Finance lease liabilities-current portion	23,809
Note payable-current portion	100,000	215,000
Convertible debt- net		67,500
Total Current Liabilities	2,553,601	2,022,322
LONG-TERM LIABILITIES:
Note payable-net of current portion	168,419
Finance lease liabilities-net of current portion	103,688
Total Liabilities	2,825,708	2,022,322
Commitments and Contingencies
STOCKHOLDERS’ EQUITY:
Preferred stock, $.001 par value, 10,000,000 shares authorized, -0- outstanding
Common stock, $.001 par value, 250,000,000 shares authorized; 6,126,509 and 5,441,100 shares issued and outstanding at October 31, 2020 and January 31, 2020, respectively	6,127	5,441
Additional paid-in-capital	16,831,173	9,072,573
Accumulated other comprehensive loss	(304)	(304)
Accumulated deficit	(9,582,909)	(8,902,277)
Total Stockholders’ Equity	7,254,087	175,433
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY	$ 10,079,795	$ 2,197,755

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parentheticals) - $ / shares	Oct. 31, 2020	Jan. 31, 2020
Statement of Financial Position [Abstract]
Preferred stock par value (in Dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares outstanding	0	0
Common stock, par value (in Dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized	250,000,000	250,000,000
Common stock, shares issued	6,126,509	5,441,100
Common stock, shares outstanding	6,126,509	5,441,100

Unaudited Consolidated Statemen

Unaudited Consolidated Statements of Operations and Comprehensive Loss - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Income Statement [Abstract]
Revenue	$ 391,797	$ 82,567	$ 595,611	$ 351,070
Costs and expenses:
Cost of revenues	228,772	106,126	420,648	422,879
Selling, general and administrative expenses	203,976	307,015	589,224	1,281,538
Total Costs and Expenses	432,748	413,141	1,009,872	1,704,417
Loss from operations	(40,951)	(330,574)	(414,261)	(1,353,347)
Other income (expense)
Loss on extinguishment of debt			(12,500)
Early prepayment fee on convertible debentures			(69,131)
Derivative expense		(352,136)		(352,136)
Gain (loss) on change of fair value of derivative		(70,150)	22,096	(70,150)
Interest expense	(1,618)	(414)	(206,836)	(1,559)
Total other expense	(1,618)	(422,700)	(266,371)	(423,845)
Loss before provision for income taxes	(42,569)	(753,274)	(680,632)	(1,777,192)
Provision for income taxes
Net loss	$ (42,569)	$ (753,274)	$ (680,632)	$ (1,777,192)
Net loss per share of common stock-basic and diluted (in Dollars per share)	$ (0.01)	$ (0.14)	$ (0.12)	$ (0.33)
Weighted average shares of common stock outstanding - basic and diluted (in Shares)	5,651,180	5,423,956	5,636,798	5,265,406
Other Comprehensive Loss:
Net loss	$ (42,569)	$ (753,274)	$ (680,632)	$ (1,777,192)
Foreign currency translation adjustment				(252)
Total Comprehensive Loss	$ (42,569)	$ (753,274)	$ (680,632)	$ (1,777,444)

Unaudited Consolidated Statem_2

Unaudited Consolidated Statements of Stockholders' Equity - USD ($)	Common Stock	Additional Paid In Capital	Accumulated Other Comprehensive Income (Loss)	Accumulated Deficit	Total
Balance at Jan. 31, 2019	$ 5,424	$ 8,579,890	$ (52)	$ (6,180,650)	$ 2,404,612
Balance (in Shares) at Jan. 31, 2019	5,423,956
Issuance of warrants for services		252,700			252,700
Relative fair value of warrants issued with debt		193,434			193,434
Foreign currency translation adjustment			(252)		(252)
Net loss				(1,777,192)	(1,777,192)
Balance at Oct. 31, 2019	$ 5,424	9,026,024	(304)	(7,957,842)	1,073,302
Balance (in Shares) at Oct. 31, 2019	5,423,956
Balance at Jul. 31, 2019	$ 5,424	8,832,590	(304)	(7,204,568)	1,633,142
Balance (in Shares) at Jul. 31, 2019	5,423,956
Relative fair value of warrants issued with debt		193,434			193,434
Net loss				(753,274)	(753,274)
Balance at Oct. 31, 2019	$ 5,424	9,026,024	(304)	(7,957,842)	1,073,302
Balance (in Shares) at Oct. 31, 2019	5,423,956
Balance at Jan. 31, 2020	$ 5,441	9,072,573	(304)	(8,902,277)	175,433
Balance (in Shares) at Jan. 31, 2020	5,441,100
Issuance of common stock for services	$ 5	49,995			50,000
Issuance of common stock for services (in Shares)	5,000
Sale of common stock for cash	$ 47	515,061			515,108
Sale of common stock for cash (in Shares)	46,828
Conversion of debt for common stock	$ 25	287,475			287,500
Conversion of debt for common stock (in Shares)	25,000
Reclass of warrants from liability to equity		906,678			906,678
Issuance of common stock for acquisition	$ 609	5,999,391			6,000,000
Issuance of common stock for acquisition (in Shares)	608,581
Net loss				(680,632)	(680,632)
Balance at Oct. 31, 2020	$ 6,127	16,831,173	(304)	(9,582,909)	7,254,087
Balance (in Shares) at Oct. 31, 2020	6,126,509
Balance at Jul. 31, 2020	$ 5,518	10,831,782	(304)	(9,540,340)	1,296,656
Balance (in Shares) at Jul. 31, 2020	5,517,928
Issuance of common stock for acquisition	$ 609	5,999,391			6,000,000
Issuance of common stock for acquisition (in Shares)	608,581
Net loss				(42,569)	(42,569)
Balance at Oct. 31, 2020	$ 6,127	$ 16,831,173	$ (304)	$ (9,582,909)	$ 7,254,087
Balance (in Shares) at Oct. 31, 2020	6,126,509

Unaudited Consolidated Statem_3

Unaudited Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Cash flows from operating activities:
Net loss	$ (680,632)	$ (1,777,192)
Adjustments to reconcile net loss to net cash used in operating activities:
Expenses paid on behalf of the Company by related party	3,628
Depreciation and amortization	83,562	54,140
Derivative expense		352,136
Amortization of debt discount	202,500
(Gain) loss on change in fair value of derivative	(22,096)	70,150
Early prepayment fee on convertible debentures	69,131
Amortization of right of use asset	9,610	14,413
Loss on extinguishment of debt	12,500
Stock-based compensation	50,000	252,700
Changes in operating assets and liabilities:
Accounts receivable	(76,066)	(58,901)
Inventory	3,404
Prepaid expenses	20,167	8,808
Deferred revenue	91,166	(71,225)
Operating lease liability	(10,050)	(13,921)
Accounts payable and accrued expenses	29,267	391,961
Net Cash Used In Operating Activities	(213,909)	(776,931)
Cash flows from investing activities:
Cash received from acquisition	66,994
Cash flows from financing activities:
Proceeds from sale of common stock	515,108
Proceeds from notes payable	194,870	150,000
Payment of notes payable	(5,635)
Proceeds from sale of convertible debt and warrants		250,000
Payment on finance leases	(2,391)
Payment on convertible debt	(339,131)
Proceeds from related parties	11,567	4,250
Payment of related party payables	(44,262)	(4,250)
Net Cash Provided by Financing Activities	330,126	400,000
Effect of exchange rate on cash		(252)
Net change in cash	183,211	(377,183)
Cash and cash equivalents - Beginning of period	10,181	474,653
Cash and cash equivalents - End of period	193,392	97,470
Cash paid for:
Interest	7,488
Income taxes
Supplemental disclosure of non-cash investing and financing activities:
Common stock issued for settlement of notes payable	287,500
Derivative liability warrant reclassed to equity	906,678
Common stock and note payable issued in acquisition	$ 7,500,000

Organization and Description of

Organization and Description of Business	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
ORGANIZATION AND DESCRIPTION OF BUSINESS	1. ORGANIZATION AND DESCRIPTION OF BUSINESS Organization Nutriband Inc. (the “Company”) is a Nevada corporation, incorporated on January 4, 2016. In January 2016, the Company acquired Nutriband Ltd., an Irish company which was formed by the Company’s chief executive officer in 2012 to enter the health and wellness market by marketing transdermal patches. References to the Company relate to the Company and its subsidiaries unless the context indicates otherwise. On August 1, 2018, the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics. 4P Therapeutics is engaged in the development of a series of transdermal pharmaceutical products that are in the preclinical stage of development. Prior to the acquisition of 4P Therapeutics, the Company’s business was the development and marketing of a range of transdermal consumer patches. Most of these products are considered drugs in the United States and cannot be marketed in the United States without approval by the Food and Drug Administration (the “FDA”). The Company is not presently taking any steps to seek FDA approval of its consumer transdermal products and its consumer products are not being marketed in the United States. With the acquisition of 4P Therapeutics, 4P Therapeutics’ drug development business became one of the Company’s principal businesses. The Company’s approach is to use generic drugs that are off patent and incorporate them into the Company’s transdermal drug delivery system. Although these medications have received FDA approval in oral or injectable form, the Company needs to conduct a transdermal product development program which will include the preclinical and clinical trials that are necessary to receive FDA approval before the Company can market any pharmaceutical transdermal products. On August 25, 2020, the Company formed Pocono Pharmaceuticals Inc. (“Pocono”), a wholly owned subsidiary of the Company. On August 31, 2020, the Company acquired certain assets and liabilities associated with the Transdermal, Topical, Cosmetic, and Nutraceutical business of Pocono Coated Products LLC (“PCP”). The net assets were contributed to Pocono. Included in the transaction, the Company also acquired 100% of the membership interests of Active Intelligence LLC (“Active Intelligence”), who became a wholly owned subsidiary of the Company. The purchase price was (i) $6,000,000 paid with the issuance of 608,519 shares in the Company’s common stock of Nutriband at a value of the average price of the previous 90 days at the date of the closing, and (ii) a promissory note of the note of the Company in the principal amount of $1,500,000 which is due upon the earlier of (a) twelve (12) months from issuance or (b) immediately following a capital raise of no less the $4,000,000 and/or a public offering of no less than $4,000,000. See Note 3 for further details of the acquisition. Pocono is a coated products manufacturing entity that takes advantage of its unique process capabilities and experience. Pocono helps its customers with product design and development along with manufacturing to bring new products to market with minimal capital investment. Pocono’s competitive edge is a low-cost manufacturing base: a result of its unique processes and state of the art material technology. Active Intelligence manufactures activated kinesiology tape. The tape has transdermal and topical properties. This tape is used same as traditional kinesiology tape. In December 2019, COVID-19 emerged and has subsequently spread world-wide. The World Health Organization has declared COVID-19 a pandemic resulting in federal, state and local governments and private entities mediating various restrictions, including travel restrictions, restrictions on public gatherings, stay at home orders and advisories and quarantining people who may have been exposed to the virus. The effect of these orders, government imposed quarantines and measures the Company would take, such as work-at-home policies, may negatively impact productivity, disrupt our business and could delay our clinical programs and timelines, the magnitude of which will depend, in part, on the length and severity of the restrictions and disruptions in our operations could negatively impact our business, operating results and financial condition. Further, quarantines, shelter-in-place and similar government orders, or the perception that such orders, shutdowns, or other restrictions on the conduct of business could occur, related to COVID-19 or other infectious diseases could impact personnel at third-party manufacturing facilities in the United States and other countries, or the availability or cost of materials, which could disrupt our supply chain. Reverse Stock Split On June 25, 2019, the Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock. The reverse split became effective in the marketplace on July 24, 2019. All share and per share information in these financial statements retroactively reflect the reverse split. Going Concern The Company’s consolidated financial statements for the nine months ended October 31, 2020 have been prepared on a going concern basis which contemplates the realization of assets and settlement of liabilities in the normal course of business. For the nine months ended October 31, 2020, the Company generated revenue of $595,611 on which it recorded cost of revenues of $420,648 and a loss from operations of $414,261. Subsequent to January 31, 2020, because of the lack of available cash and the decline in business resulting in part from the effects of the COVID-19 pandemic, the Company has temporarily closed its operations, and does not expect it will be able to commence operations until it receives substantial funding. Successful business operations and its transition to attaining profitability are dependent upon obtaining significant additional financing, generating revenue primarily from its professional services to cover its overhead, developing its products, and obtaining FDA approval to market any product it develops and implementing a marketing program for such products. These factors raise substantial doubt about ability of the Company to continue as a going concern for a period of at least one year from the date of these financial statements. Without such financing, the Company may not be able to continue in business. The financial statements do not include any adjustments that might result from the outcome of this uncertainty.

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	2. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Unaudited Interim Financial Statements The consolidated balance sheet as of October 31, 2020 and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods pursuant to Rule 8-03 of Regulation S-X, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2020 was derived from audited financial statements of the Company. Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018 and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020. The wholly owned subsidiaries are as follows: 4P Therapeutics LLC Pocono Pharmaceuticals Inc. and its wholly owned subsidiary Active Intelligence LLC Use of Estimates The discussion and analysis of our plan of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect our reported results of operations and the amount of reported assets and liabilities. Some accounting policies involve judgments and uncertainties to such an extent there is reasonable likelihood that materially different amounts could have been reported under different conditions, or if different assumptions had been used. Actual results may differ from estimates and assumptions used in the preparation of our consolidated financial statements. The Company’s significant policies are summarized in Note 1 of the Company’s Annual Report on Form 10-K for the year ended January 31, 2020. There were no significant changes to the accounting policies during the nine months ended October 31, 2020, and the Company does not expect that the adoption of other accounting pronouncements will have a material impact on its financial statements. Revenue Recognition The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606. Revenue Service Types The following is a description of the Company’s revenue service types, which include professional services and sale of goods: ● Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged. ● Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor and sales related to consumer products sold by Pocono and Active Intelligence. Upon receipt of a purchase order, the Company has the order filled and shipped. Contracts with Customers A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. Deferred Revenue Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month. All revenue recognized in the statement of operations is revenue from contracts with customers. Disaggregation of Revenues The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location. Revenue by service type: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Sale of goods $ 347,216 $ - $ 467,986 $ 142,450 Services 44,581 82,567 127,625 208,620 Total $ 391,797 $ 82,567 $ 595,611 $ 351,070 Revenue by geographic location: Three Months Ended Nine Months Ended 2020 2019 2020 2019 United States $ 155,083 $ 82,567 $ 238,127 $ 208,620 Non-United States 236,714 - 357,484 142,450 $ 391,797 $ 82,567 $ 595,611 $ 351,070 Accounts receivable Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the nine months ended October 31, 2020 and 2019, the Company recorded no bad debt expense for doubtful accounts related to account receivable. Inventories Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity). Property, Plant and Equipment The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the asset. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows: Lab equipment 5-10 years Furniture, fixtures and equipment 3 years Intangible Assets Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition of 4P Therapeutics in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years. Goodwill Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31, 2020, in connection with the Company’s acquisition of certain assets and liabilities of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $6,467,961. As of October 31, 2020, Goodwill amounted to $8,187,196. Long-lived Assets Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value. Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of October 31, 2020, and 2019, there were 141,830 and 133,214 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive. Stock-Based Compensation ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees. Fair Value Measurements FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be to measure fair value. The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: Level 1 - Observable inputs such as quoted market prices in active markets. Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable. Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying value of the Company’s financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. Derivative liabilities are determined based on “Level 3” inputs, which are significant and unobservable and have the lowest priority. The recorded values of all other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations. See Note 6 for further information. Derivative Liabilities The Company accounts for derivative instruments in accordance with ASC Topic 815, “Derivatives and Hedging” and all derivative instruments are reflected as either assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments. Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market participants. In general, the Company’s policy in estimating fair values is to first look at observable market prices for identical assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency utilized in measuring financial instruments at fair value as discussed above. As of October 31, 2020, and January 31, 2020, the Company had a $-0- and $928,774 derivative liability, respectively. Fair value estimates are made at a specific point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates. Recent Accounting Standards The Company has implemented all new pronouncements, including the adoption of ASU 2018-13, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

Acquisition of Business

Acquisition of Business	9 Months Ended
	Oct. 31, 2020
Business Combinations [Abstract]
ACQUISITION OF BUSINESS	3. ACQUISITION OF BUSINESS On August 31, 2020, the Company entered into a Purchase Agreement (“Agreement”), with Pocono Coated Products (“PCP”) and Active Intelligence LLC (“Active Intelligence”), pursuant to which (1) PCP agreed to sell the Company certain of the assets and liabilities associated with its Transdermal, Topical, Cosmetic, and Nutraceutical business, including all the equipment, intellectual property and trade secrets, cash balances, receivables, bank accounts and inventory, free and clear of all liens, except for certain lease obligations (the “PCP Segment”), and (2) Active Intelligence agreed to sell the Company 100% of its membership interest (collectively the “Assets”). The net Assets acquired were contributed to Pocono Pharmaceuticals Inc, a newly formed wholly owned subsidiary of the Company. The purchase price for the Assets was (i) $6,000,000 paid with the issuance of 608,519 shares in the Company’s common stock of Nutriband at a value of the average price of the previous 90 days at the date of Closing (the “Shares”), and (ii) a promissory note of the Company in the principal amount of $1,500,000 (the “Note”) which is due upon the earlier of (a) twelve (12) from issuance, or (b) immediately following a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Michael Myer, the CEO of PCP, has been elected to the Board of Directors of the Company for period of one year at the annual meeting of shareholders of the Company held in October 2020. The Agreement provides that it is effective August 31, 2020, on which date the parties also entered into an escrow agreement (the “Escrow Agreement”), with legal counsel serving as the escrow agent, providing for holding of the Note, certificate for the shares, and title to the Assets (held in a special purpose entity controlled by the escrow agent) as collateral security for completion of all closing conditions under the Agreement. On that date, the parties also entered into a security agreement granting PCP a security interest in all proceeds of the Assets held as collateral under the Escrow Agreement. The purpose of the Company entering into the transaction is to enhance the transdermal products operations of the Company. The PCP Segment was a portion of an existing vendor of Nutriband. Some of the expenses leading up to the acquisition date are related party revenues. The fair value of consideration given was allocated to the net tangible assets acquired. Under U.S. GAAP, both the PCP segment and Active Intelligence were considered to be businesses and, as such, the transaction was accounted for under the acquisition method of accounting. Details of the net assets acquired are as follows: Provisional Recognized on Acquisition Common stock issued $ 6,000,000 Note payable issued 1,500,000 $ 7,500,000 Cash 66,994 Accounts receivable 1,761 Inventory 42,613 Equipment 1,227,171 Accounts payable and accrued expenses (10,577 ) Deferred revenue (26,851 ) Debt (269,072 ) Net assets acquired $ 1,032,039 Goodwill (provisional) 6,467,961 $ 7,500,000 The following unaudited pro forma condensed financial information presents the combined results of operations of the Company, the PCP segment and Active Intelligence, as if the acquisition occurred as part of the beginning of cash period presented. The unaudited pro forma condensed financial information is not intended to represent or be indicative of the consolidated results of operations of the Company that would have been reported had the acquisition occurred at the beginning of the period presented and should not be taken as being representation of the future consolidated results of operations of the Company. Nine Months Ended October 31, 2020 2019 As As Reported Proforma Reported Proforma Net revenue $ 595,611 $ 2,167,208 $ 351,070 $ 2,362,122 Net loss (680,632 ) (609,741 ) (1,777,192 ) (1,540,409 ) Loss per common share - basic and diluted (0.12 ) (0.10 ) (0.33 ) (0.26 ) Since the date of acquisition, Pocono had net revenues of $186,917 and incurred a net profit of $30,416.

Property and Equipment

Property and Equipment	9 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
PROPERTY AND EQUIPMENT	4. PROPERTY AND EQUIPMENT October 31, January 31, 2020 2020 Lab equipment $ 1,371,756 $ 144,585 Furniture, fixtures and equipment 19,643 19,643 1,391,399 164,228 Less: Accumulated depreciation (108,959 ) (53,199 ) Net Property and Equipment $ 1,282,440 $ 111,029 Depreciation expense amounted to $55,760 and 26,338 for the nine months ended October 31, 2020 and 2019, respectively

Notes Payable_Convertible Debt

Notes Payable/Convertible Debt	9 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
NOTES PAYABLE/CONVERTIBLE DEBT	5. NOTES PAYABLE/CONVERTIBLE DEBT Notes Payable On March 21, 2020, the Coronavirus Aid Relief and Economic Security Act (“CARES ACT” was enacted. The CARES ACT established the Paycheck Protection Program (“PPP”) which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company’s subsidiary, 4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of October 31, 2020. The note matures June 17, 2022 and accrues interest at 0.98% per year. In March 2020, a minority shareholder who had previously made loans of $215,000 as of January 31, 2020, made an additional loan to the Company in the amount of $60,000, increasing the total loans from the stockholder to $275,000. The loans are interest free and due upon demand. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal balance of $275,000. The transaction resulted in a loss on extinguishment of $12,500. In July 2020, the minority shareholder made an additional loan to the Company in the amount of $100,000. The loan is interest free and due upon demand. The loan was outstanding as of October 31, 2020. Active Intelligence, the Company’s newly acquired subsidiary, entered into an agreement with the Carolina Small Business Development Fund for a line of credit of $160,000 due October 16, 2029 with interest of 5% per year. The loan requires monthly payments of principal and interest of $1,697. As of October 31, 2020, the amount due was $133,549, of which $19,000 is current. Pocono has two finance leases secured by equipment. The leases mature in 2025 and 2026. The incremental borrowing rate is 5.0%. As of October 31, 2020, the minimum lease payments are as follow: Years ending January 31, 2021 $ 5,953 January 31, 2022 24,738 January 31, 2023 26,295 January 31, 2024 27,948 January 31, 2025 26,361 January 31, 2026 16,202 Total $ 127,497 Related Party Payable As of January 31, 2020, the Company owed its chief financial officer and chief operating officer $29,067 from advances made to the Company. During the nine months ended October 31, 2020, the Company’s chief financial officer paid expenses of $3,628 on behalf of the Company, the Company’s chief executive officer and chief operating officer advanced the Company $11,567 and the officers were repaid $44,262. As of October 31, 2020, the amount the officers were fully repaid. On August 31, 2020, in connection with the Company’s acquisition of Pocono Products LLC, the Company issued to Pocono Coated Products LLC a promissory note in the amount of $1,500,000 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a relate party, is a shareholder of the Company. Convertible Debt On October 30, 2019, the Company entered into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing of $250,000. The notes are convertible at a conversion price equal to the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing of the first to occur of (a) the next public offering of the Company’s securities or (b) the next private placement of the Company’s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender. The embedded conversion option qualified for derivative accounting and bifurcation under ASC 815-15 Derivative and Hedging. The initial fair of the conversion feature was $128,870 and the fair value of the warrants in connection with the notes were valued at $888,789 and were recorded based on their relative fair values. A debt discount to the note payables of $270,000 and an initial derivative expense of $767,650 was recorded. The debt discount will be amortized over the life of the note. Amortization of the debt discount for the year ended January 31, 2020 was $67,500. As of January 31, 2020, the debt discount remaining was $202,500. On March 25, 2020, the Company prepaid the convertible notes in the principal amount of $270,000 from the proceeds of a private placement. The total payments, including a prepayment fee of $69,131 and accrued interest, was $345,565. As a result of the payment of the notes, the derivative liability, which was $928,774 as of January 31, 2020, was reduced to zero. The warrants are no longer a derivative liability based on the notes being paid in full. See Note 6 for further information. Interest expense for the nine months ended October 31, 2020 including the amortization of the debt discount was $205,900.

Intangible Assets

Intangible Assets	9 Months Ended
	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
INTANGIBLE ASSETS	6. INTANGIBLE ASSETS As of October 31, 2020, and January 31, 2020, intangible assets consisted of intellectual property, customer base and trademarks, net of amortization, as follows: October 31, January 31, 2020 2020 Customer base $ 136,500 $ 136,500 Intellectual property 234,200 234,200 Total 370,700 370,700 Less: Accumulated amortization (83,802 ) (56,000 ) Net Intangible Assets $ 286,898 $ 314,700 The value of the intangible assets, consisting of intellectual property and customer base has been recorded at their fair value by the Company after completing a valuation and are being amortized over a period of ten years. Amortization expense for the nine months ended October 31, 2020 and 2019 was $27,802 and $27,802, respectively. Estimated Amortization: Total Year Ended January 31, 2021 $ 9,267 2022 37,070 2023 37,070 2024 37,070 2025 and thereafter 166,421 $ 286,898

Derivative Liabilities

Derivative Liabilities	9 Months Ended
	Oct. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
DERIVATIVE LIABILITIES	7. DERIVATIVE LIABILITIES The embedded conversion option of the convertible debentures described and the warrants issued in Note 4 contain conversion features that qualify for embedded derivative classification. The fair value of the liabilities will be re-measured at the end of every reporting period and the change in fair value will be reported in the statement of operations as a gain or loss on derivative financial instruments. The table below sets forth a summary in the fair value of the Company’s Level 3 financial liabilities: October 31, Balance at the beginning of the period $ 928,774 Derivative liability warrants reclassed to equity (906,678 ) Change in value of embedded conversion option (22,096 ) $ - The Company uses Level 3 inputs for its valuation methodology for the embedded conversion option liabilities (Binomial Model) and for its valuation methodology of the warrants reclassed to equity (Black Scholes Model) based on various assumptions. At issuance, the expected volatility was 158.3%; risk-free interest rate of 1.58%; and expected term of one year. For the revaluation January 31, 2020, the expected volatility was 184.4%; risk-free rate of return of 1.43%; and expected term of nine months.

Related Party Transactions

Related Party Transactions	9 Months Ended
	Oct. 31, 2020
Related Party Transactions [Abstract]
RELATED PARTY TRANSACTIONS	8. RELATED PARTY TRANSACTIONS a) The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into an agreement to acquire 4P Therapeutics. In connection with the terms of the acquisition of 4P Therapeutics, the former owner received $400,000 in cash and 250,000 shares of common stock valued at $1,850,000. The former owner was not a director of the Company when the acquisition agreement was signed. b) On February 19, 2019, the Company granted an executive officer an option to purchased 25,000 shares of the Company’s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise. The fair value of the warrant on the date of grant using the Black Scholes model was $252,700 and was expensed during the six months ended July 31, 2019. The warrant expired unexercised on May 19, 2019. c) As of January 31, 2020, the Company owed its chief financial officer and chief operating officer $29,067 from advances made to the Company. During the nine months ended October 31, 2020, the Company’s chief financial officer paid expenses of $3,628 on behalf the Company, the Company’s chief executive officer and chief operating officer advanced the Company $11,567 and the officers were repaid $35,195. As of October 31, 2020, the Company owed the officers $-0-. d) In connection with the acquisition of the PCP Segment (Note 3), some customer collections and payments for certain expenses had not yet transitioned to Pocono Pharmaceuticals bank accounts and therefore a net balance receivable is due from Pocono Coated Products LLC, a related entity. Pocono Coated Products LLC is a shareholder of Nutriband and is an entity controlled by the family of a Nutriband director. This transition was completed as of October 2020. The transactions included revenue of $121,563, purchase of materials of $70,230, expenses paid of $9,324 and finance payments of $3,307. As of October 31, 2020, Pocono Coated Products LLC owed the Company a net amount of $39,777, comprised of $69,855 of trade accounts receivable and $30,078 in Accounts payable and Accrued expenses on the balance sheet. The PCP Segment was a former vendor of Nutriband and prior to September 1, 2020, these expenses have not been eliminated as intercompany expenses, like they are after the acquisition date. These expenses amounted to $173,310.

Stockholders' Equity

Stockholders' Equity	9 Months Ended
	Oct. 31, 2020
Stockholders' Equity Note [Abstract]
STOCKHOLDERS' EQUITY	9. STOCKHOLDERS’ EQUITY Preferred Stock On January 15, 2016, the board of directors of the Company approved a certificate of amendment to the articles of incorporation and changed the authorized capital stock of the Company to include and authorize 10,000,000 shares of Preferred Stock, par value $0.001 per share. On May 24, 2019, the board of directors created a series of preferred stock consisting of 2,500,000 shares designated as the Series A Convertible Preferred Stock (“Series A Preferred Stock”). On June 20, 2019, the Series A preferred Stock was terminated, and the 2,500,000 shares were restored to the status of authorized but unissued shares of Preferred Stock, without designation as to series, until such stock is once more designated as part of a particular series by the board of directors. Common Stock On June 25, 2019, the Company effected a one-for four reverse split, pursuant to which each share of common stock became converted into 0.25 shares of common stock, and the Company decreased its authorized common stock from 100,000,000 to 25,000,000 shares. On January 27, 2020, the Company amended its articles of incorporation to increase its authorized common shares from 25,000,000 shares to 250,000,000 shares. On March 22, 2020, the Company issued in a private placement 46,828 units at a price of $11 per unit. Each unit consisted of one share of common stock and a warrant to purchase one share of common stock at an exercise price of $14 per share. The warrants expire April 30, 2023. The Company issued a total of 46,828 shares of common stock and warrants to purchase 46,828 shares of common stock. The Company received proceeds of $515,108. In March 2020, a minority shareholder who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500. On June 30, 2020, the Company issued 5,000 shares to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000, which is included in selling and general administrative expense for the nine months ended October 31, 2020. On August 31, 2020, the Company acquired the membership interests in Pocono Coated Products LLC and issued 608,519 shares of its common stock, valued at $6,000,000, and issued a promissory note in the amount of $1,500,000. See Note 3 for further information.

Warrants

Warrants	9 Months Ended
	Oct. 31, 2020
Warrants [Abstract]
WARRANTS	10. WARRANTS The following table summarizes the changes in warrants outstanding and the related price of the shares of the Company’s common stock issued to non-employees of the Company. Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2020 70,000 $ 18.93 1.53 years $ - Granted 91,828 12.53 3.00 years - Expired/Cancelled (20,000 ) 14.00 - - Exercised - - - - Outstanding-period ending October 31, 2020 141,828 $ 11.99 2.16 years $ 285,000 Exercisable - period ending October 31, 2020 141,828 $ 11.99 2.16 years $ 285,000 As result of the terms of a completed private placement, the warrants to purchase 50,000 shares at the lesser of (i) $20.90 or, (ii) if the Company completes a private offering of its common stock, 110% of the initial public offering price of the Common Stock in the public offering, became a warrant to purchase 95,000 shares at $11 per share, subject to adjustment pursuant to the antidilution provisions of the warrant. The Company recorded a derivative liability for the warrants in the amount of $906,678 and reclassed the derivative liability to additional paid-in capital as of October 31, 2020. In connection with a private placement in March 2020, the Company issued warrants to purchase 46,828 shares of its common stock at $14 per share. The warrants expire April 30, 2023. (See Note 9). The following table summarizes additional information relating to the warrants outstanding as of October 31, 2020: Range of Exercise Prices Number Outstanding Remaining Contractual Life(Years) Exercise Price for Shares Outstanding Number Exercisable Exercise Price for Shares Exercisable Intrinsic Value $ 11.00 95,000 2.25 $ 11.00 95,000 $ 11.00 $ 237,500 $ 14.00 46,828 2.75 $ 14.00 46,828 $ 14.00 $ -

Contingencies

Contingencies	9 Months Ended
	Oct. 31, 2020
Commitments and Contingencies Disclosure [Abstract]
CONTINGENCIES	11. CONTINGENCIES Legal Proceedings On July 27, 2018, the Company commenced an action in the Circuit Court of the Ninth Judicial Circuit in and for Orange County, Florida, against Advanced Health Brands, Inc., Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Laura Fillman and John Baker, together with a Motion for Temporary Injunction Without Notice and a Motion for Prejudgment Writ of Replevin arising from the Company’s decision to seek to rescind for misrepresentation the agreement by which the Company acquired advanced Health Brands, Inc. for 1,250,000 shares of common stock valued at $2,500,000 and seek return of the shares. On August 2, 2018, the court entered a Temporary Injunction Without Notice and an Order to Show Cause against the defendants. Defendants Kalmar, Murphy, Polly-Murphy, and Baker filed a Motion to Dismiss the Company’s Verified Complaint, Motion to Dissolve Temporary Injunction Without Notice and Response to Order to Show Cause, and Motion to Compel Arbitration. On January 4, 2019, the court dismissed the Company’s complaint with prejudice, and directed the defendants to assign the Company within 30 days, the six patents never duly transferred to the Company. On February 1, 2019, the Company appealed the court’s order. Pursuant to a settlement agreement with one of the defendants, that defendant returned the 50,000 shares which had been issued to her, and the shares were cancelled as of January 31, 2019. On June 7, 2019, the individual defendants (other than the defendant whom the Company has a settlement agreement), filed a motion for sanctions and civil contempt against us, which generally claimed that we failed to comply with the Court’s January 4, 2019 order by refusing to issue the Ruling 144 letters that would allow the defendants to transfer their shares of common stock. On October 29, 2019, the Court denied the Defendants motion. On March 20, 2020, the Florida district court of appeal reversed the lower court ruling in the Florida state court action that dismissed our complaint, with prejudice, and gave us leave to file an amended complaint. On July 7, 2020, Defendants filed Notice for Trial, requesting the court to set a trial date. The Company and defendants have served their first set of interrogatories on each other and have filed answers and responses to each other’s first set of interrogatories. On August 22, 2018, four of the defendants in the Florida action described in the previous paragraph filed a complaint against the Company in the Franklin County, Ohio Court of Common Pleas seeking a declaratory judgment permitting them to sell the shares of common stock they received pursuant to the acquisition agreement. The parties have agreed to a stay pending the outcome of the Florida litigation. On April 29, 2019, the Company filed a securities fraud action in the U.S. District Court for the Eastern District of New York against Raymond Kalmar, Paul Murphy, Michelle Polly-Murphy, Advanced Health Brands and TD Therapeutic, Inc. In the complaint the Company alleges that in 2017, the defendants fraudulently and deceitfully obtained 1,250,000 shares of common stock by orchestrating a months-long scheme to defraud the Company. The Company is seeking the return of the shares of common stock and monetary damages resulting from the defendants’ fraudulent conduct. The defendants filed a motion to dismiss the complaint on August 23, 2019, and on September 13, 2019 the Company filed its response. On July 20, 2020, the Court denied the defendant’s motion to dismiss the complaint, and the parties have recently commenced the discovery phase of the litigation. No trial date has been scheduled by the Court. Employment Agreements The Company has employment agreements with its chief executive officer and chief financial officer dated April 23, 2019 pursuant to which we agree to employ them as chief executive officer and chief financial officer, respectively. The agreement also provides that the Company will include each of them as our nominee for director. The agreements have a term ending on January 31, 2024 and continuing on a year-to-year basis thereafter unless terminated by either party on not less than 30 days’ notice given prior to the expiration of the initial term or one-year extension. Pursuant to the employment agreements at January 31, 2020, the chief executive officer is receiving compensation at an annual rate of $42,000, and chief financial officer is not currently receiving any compensation. Commencing with the month in which the Company has raised at least $2,500,000 from public or private financing of its equity securities, they will each receive salary at the annual rate of $170,000. The Company has an employment agreement May 16, 2018 with its president pursuant to which the Company employed him as president for a term with no expiration date at annual salary of $60,000, which may be paid in stock or cash. The president serves on a part-time basis. The Company has an employment agreement dated February 19, 2019 with its chief scientific officer pursuant to which the Company agrees to employ him as chief scientific officer for annual compensation of $60,000, payable in cash or stock, as the Company may elect. The agreement has a term ending on January 31, 2021 and continues thereafter on a quarter-to-quarter basis unless terminated by either party on 30 days’ notice. The chief scientific officer serves on a part-time basis.

Accounting Policies, by Policy

Accounting Policies, by Policy (Policies)	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Unaudited Interim Financial Statements	Unaudited Interim Financial Statements The consolidated balance sheet as of October 31, 2020 and the consolidated statements of operations, stockholders’ equity, and cash flows for the periods presented have been prepared by the Company and are unaudited. The consolidated financial statements are prepared in accordance with the requirements for unaudited interim periods pursuant to Rule 8-03 of Regulation S-X, and consequently, do not include all disclosures required to be made in conformity with accounting principles generally accepted in the United States of America. In the opinion of management, all adjustments (consisting solely of normal recurring adjustments) necessary to present fairly the financial position, results of operations, changes in stockholders’ equity and cash flows for all periods presented have been made. The information for the consolidated balance sheet as of January 31, 2020 was derived from audited financial statements of the Company.
Principles of Consolidation	Principles of Consolidation The consolidated financial statements of the Company include the Company and its wholly owned subsidiaries. All material intercompany balances and transactions have been eliminated. The operations of 4P Therapeutics are included in the Company’s financial statements from the date of acquisition of August 1, 2018 and the operations of Pocono and Active Intelligence are included in the Company’s financial statements from the date of acquisition of September 1, 2020. The wholly owned subsidiaries are as follows: 4P Therapeutics LLC Pocono Pharmaceuticals Inc. and its wholly owned subsidiary Active Intelligence LLC
Use of Estimates	Use of Estimates The discussion and analysis of our plan of operations is based upon our consolidated financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States of America. The preparation of our consolidated financial statements requires us to make estimates and assumptions that affect our reported results of operations and the amount of reported assets and liabilities. Some accounting policies involve judgments and uncertainties to such an extent there is reasonable likelihood that materially different amounts could have been reported under different conditions, or if different assumptions had been used. Actual results may differ from estimates and assumptions used in the preparation of our consolidated financial statements. The Company’s significant policies are summarized in Note 1 of the Company’s Annual Report on Form 10-K for the year ended January 31, 2020. There were no significant changes to the accounting policies during the nine months ended October 31, 2020, and the Company does not expect that the adoption of other accounting pronouncements will have a material impact on its financial statements.
Revenue Recognition	Revenue Recognition The Company recognized revenue in accordance with Topic 606 “Revenue from Contracts with Customers. Topic 606 is based on principles that govern the recognition of revenue at an amount an entity expects to be entitled when products are transferred to a customer. The Company adopted the guidance under the new revenue standards using the modified retrospective method effective February 1, 2018 and determined no cumulative effect adjusted to retained earnings was necessary upon adoption. Topic 606 requires the Company to recognize revenues when control of the promised goods or services and receipt of payment is probable. The Company recognizes revenue based on the five criteria for revenue recognition established under Topic 606: 1) identify the contract, 2) identify separate performance obligations, 3) determine the transaction price, 4) allocate the transaction price among the performance obligations, and 5) recognize revenue as the performance obligations are satisfied. Upon adoption, Topic 606 replaced most existing revenue recognition guidance in U.S. GAAP. The adoption of Topic the new revenue recognition standards did not have any impact on its consolidated financial statements since the Company did not recognize any revenue prior to the third quarter of 2018, and all revenue is recognized pursuant to Topic 606. Revenue Service Types The following is a description of the Company’s revenue service types, which include professional services and sale of goods: ● Professional services include contract research and development related services with clients in the life sciences field on an as-needed basis. Deliverables primarily consist of detailed findings and conclusion reports provided to the client for each given research project engaged. ● Sales revenues are derived from the sale of products. To date, sales related to consumer products sold to the Company’s South Korean distributor and sales related to consumer products sold by Pocono and Active Intelligence. Upon receipt of a purchase order, the Company has the order filled and shipped. Contracts with Customers A contract with a customer exists when (i) the Company enters into an enforceable contract with a customer that defines each party’s rights regarding the goods or services to be transferred and identifies the payment terms related to these goods or services, (ii) the contract has commercial substance and, (iii) the Company determines that collection of substantially all consideration for services that are transferred is probable based on the customer’s intent and ability to pay the promised consideration. Deferred Revenue Deferred revenue is a liability related to a revenue producing activity for which revenue has not yet been recognized. The Company records deferred revenue when it receives consideration from a contract before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service to the customer, and is the unit of account in the new revenue standard. The contract transaction price is allocated to each distinct performance obligation and recognized as revenue when, or as, the performance obligation is satisfied. For the Company’s different revenue types, the performance obligation is satisfied at different times. The Company’s performance obligations include providing products and professional services in the area of research. The Company recognizes product revenue performance obligations in most cases when the product has shipped to the customer. When the Company performs professional service work, it recognizes revenue when it has the right to invoice the customer for the work completed, which typically occurs on a monthly basis for the work performed during that month. All revenue recognized in the statement of operations is revenue from contracts with customers. Disaggregation of Revenues The Company disaggregates its revenue from contracts with customers by service type and by geographical location. The following tables set forth revenue by service type and by geographical location. Revenue by service type: Three Months Ended Nine Months Ended 2020 2019 2020 2019 Sale of goods $ 347,216 $ - $ 467,986 $ 142,450 Services 44,581 82,567 127,625 208,620 Total $ 391,797 $ 82,567 $ 595,611 $ 351,070 Revenue by geographic location: Three Months Ended Nine Months Ended 2020 2019 2020 2019 United States $ 155,083 $ 82,567 $ 238,127 $ 208,620 Non-United States 236,714 - 357,484 142,450 $ 391,797 $ 82,567 $ 595,611 $ 351,070
Accounts receivable	Accounts receivable Trade accounts receivable are recorded at the net invoice value and are not interest bearing. The Company maintains allowances for doubtful accounts for estimated losses from the inability of its customers to make required payments. The Company determines its allowances by both specific identification of customer accounts where appropriate and the application of historical loss to non-applicable accounts. For the nine months ended October 31, 2020 and 2019, the Company recorded no bad debt expense for doubtful accounts related to account receivable.
Inventories	Inventories Inventories are valued at the lower of cost and reasonable value determined using the first-in, first-out (FIFO) method. Net reasonable value is the estimated selling price in the ordinary course of business, less applicable variable selling expenses. The cost of finished goods and work in process is comprised of material costs, direct labor costs and other direct costs and related production overheads (based on normal operating capacity).
Property, Plant and Equipment	Property, Plant and Equipment The Company depreciates its plant and equipment on a straight-line basis over the estimated useful life of the asset. Property, plant and equipment is stated at historical cost. Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows: Lab equipment 5-10 years Furniture, fixtures and equipment 3 years
Intangible Assets	Intangible Assets Intangible assets include trademarks, intellectual property and customer base acquired through business combinations. The Company accounts for Other Intangible Assets under the guidance of ASC 350, “Intangibles-Goodwill and Other.” The Company capitalizes certain costs related to patent technology. A substantial component of the purchase price related to the Company’s acquisition of 4P Therapeutics in 2018 has also been assigned to intellectual property and other intangibles. Under the guidance, other intangible assets with definite lives are amortized over their estimated useful lives. Intangible assets with indefinite lives are tested annually for impairment. Trademarks, intellectual property and customer base are being amortized over their estimated useful lives of ten years.
Goodwill	Goodwill Goodwill represents the difference between the total purchase price and the fair value of assets (tangible and intangible) and liabilities at the date of acquisition. Goodwill is reviewed for impairment annually on January 31, and more frequently as circumstances warrant, and written down only in the period in which the recorded value of such assets exceeds their fair value. The Company does not amortize goodwill in accordance with ASC 350. On August 31, 2020, in connection with the Company’s acquisition of certain assets and liabilities of Pocono Coated Products LLC and Active Intelligence LLC, the Company recorded Goodwill of $6,467,961. As of October 31, 2020, Goodwill amounted to $8,187,196.
Long-lived Assets	Long-lived Assets Management reviews long-lived assets for potential impairment whenever significant events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable. An impairment exists when the carrying amount of the long-lived asset is not recoverable and exceeds its fair value. The carrying amount of a long-lived asset is not recoverable if it exceeds the sum of the estimated undiscounted cash flows expected to result from the use and eventual disposition of the asset. If an impairment exists, the resulting write-down would be the difference between the fair market value of the long-lived asset and the related book value.
Earnings per Share	Earnings per Share Basic earnings per share of common stock is computed by dividing net earnings by the weighted average number of shares of common stock outstanding during the period. Diluted earnings per share is computed by dividing net earnings by the weighted average number of shares of common stock and potential shares of common stock outstanding during the period. Potential shares of common stock consist of shares issuable upon the exercise of outstanding options and common stock purchase warrants. As of October 31, 2020, and 2019, there were 141,830 and 133,214 common stock equivalents outstanding, respectively, that were not included in the calculation of dilutive earnings per share as their effect would be anti-dilutive.
Stock-Based Compensation	Stock-Based Compensation ASC 718, “Compensation - Stock Compensation,” prescribes accounting and reporting standards for all share-based payment transactions in which employee services, and, since February 1, 2019, non-employees, are acquired. Transactions include incurring liabilities, or issuing or offering to issue shares, options and other equity instruments such as employee stock ownership plans and stock appreciation rights. Share-based payments to employees, including grants of employee stock options, are recognized as compensation expense in the financial statements based on their fair values. That expense is recognized over the period during which an employee is required to provide services in exchange for the award, known as the requisite service period (usually the vesting period). As of February 1, 2019, pursuant to ASC 2018-07, ASC 718 was applied to stock-based compensation for both employees and non-employees.
Fair Value Measurements	Fair Value Measurements FASB ASC 820, “Fair Value Measurements and Disclosure” (“ASC 820”), defines fair value as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between participants on the measurement date. ASC 820 also establishes a fair value hierarchy which requires an entity to maximize the use of observable inputs and minimize the use of unobservable inputs when measuring fair value. ASC 820 describes three levels of inputs that may be to measure fair value. The Company utilizes the accounting guidance for fair value measurements and disclosures for all financial assets and liabilities and nonfinancial assets and liabilities that are recognized or disclosed at fair value in the consolidated financial statements on a recurring basis during the reporting period. The fair value is an exit price, representing the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants based upon the best use of the asset or liability at the measurement date. The Company utilizes market data or assumptions that market participants would use in pricing the asset or liability. ASC 820 establishes a three-tier value hierarchy, which prioritizes the inputs used in measuring fair value. These tiers are defined as follows: Level 1 - Observable inputs such as quoted market prices in active markets. Level 2 - Inputs other than quoted prices in active markets that are either directly or indirectly observable. Level 3 - Unobservable inputs about which little or no market data exists, therefore requiring an entity to develop its own assumptions. The carrying value of the Company’s financial instruments including cash and cash equivalents, accounts receivable, prepaid expenses, and accrued expenses approximate their fair value due to the short maturities of these financial instruments. Derivative liabilities are determined based on “Level 3” inputs, which are significant and unobservable and have the lowest priority. The recorded values of all other financial instruments approximate their current fair value because of their nature and respective short maturity dates or durations. See Note 6 for further information.
Derivative Liabilities	Derivative Liabilities The Company accounts for derivative instruments in accordance with ASC Topic 815, “Derivatives and Hedging” and all derivative instruments are reflected as either assets or liabilities at fair value on the balance sheet. The Company uses estimates at fair value to value its derivative instruments. Fair value is defined as the price to sell an asset or transfer a liability in an orderly transaction between willing and able market participants. In general, the Company’s policy in estimating fair values is to first look at observable market prices for identical assets and liabilities in active markets, when available. When these are not available, other inputs are used to model fair value such as prices of similar instruments, yield curves, volatilities, prepayment speeds, default rates and credit spreads, relying first on observable data from active markets. Depending on the availability of observable inputs and prices, different valuation models could produce materially different fair value estimates. The value presented may not represent future fair values and may not be reliable. The Company categorizes its fair value estimates in accordance with ASC 820 based on the hierarchical framework associated with the three levels of price transparency utilized in measuring financial instruments at fair value as discussed above. As of October 31, 2020, and January 31, 2020, the Company had a $-0- and $928,774 derivative liability, respectively. Fair value estimates are made at a specific point in time, based on relevant market information about the financial statement. These estimates are subjective in nature and involve uncertainties and matter of significant judgment and therefore cannot be determined with precision. Changes in assumptions could significantly affect the estimates.
Recent Accounting Standards	Recent Accounting Standards The Company has implemented all new pronouncements, including the adoption of ASU 2018-13, that are in effect and that may impact its consolidated financial statements and does not believe that there are any other new accounting pronouncements that have been issued that might have a material impact on its consolidated financial statements or results of operations.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Oct. 31, 2020
Accounting Policies [Abstract]
Schedule of disaggregation of revenues	Three Months Ended Nine Months Ended 2020 2019 2020 2019 Sale of goods $ 347,216 $ - $ 467,986 $ 142,450 Services 44,581 82,567 127,625 208,620 Total $ 391,797 $ 82,567 $ 595,611 $ 351,070
Schedule of revenue by geographic location	Three Months Ended Nine Months Ended 2020 2019 2020 2019 United States $ 155,083 $ 82,567 $ 238,127 $ 208,620 Non-United States 236,714 - 357,484 142,450 $ 391,797 $ 82,567 $ 595,611 $ 351,070
Schedule of property plant and equipment	Lab equipment 5-10 years Furniture, fixtures and equipment 3 years

Acquisition of Business (Tables

Acquisition of Business (Tables)	9 Months Ended
	Oct. 31, 2020
Business Combinations [Abstract]
Schedule of net assets acquired	Provisional Recognized on Acquisition Common stock issued $ 6,000,000 Note payable issued 1,500,000 $ 7,500,000 Cash 66,994 Accounts receivable 1,761 Inventory 42,613 Equipment 1,227,171 Accounts payable and accrued expenses (10,577 ) Deferred revenue (26,851 ) Debt (269,072 ) Net assets acquired $ 1,032,039 Goodwill (provisional) 6,467,961 $ 7,500,000
Schedule of unaudited pro forma condensed financial information	Nine Months Ended October 31, 2020 2019 As As Reported Proforma Reported Proforma Net revenue $ 595,611 $ 2,167,208 $ 351,070 $ 2,362,122 Net loss (680,632 ) (609,741 ) (1,777,192 ) (1,540,409 ) Loss per common share - basic and diluted (0.12 ) (0.10 ) (0.33 ) (0.26 )

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Oct. 31, 2020
Property, Plant and Equipment [Abstract]
Schedule of property and equipment	October 31, January 31, 2020 2020 Lab equipment $ 1,371,756 $ 144,585 Furniture, fixtures and equipment 19,643 19,643 1,391,399 164,228 Less: Accumulated depreciation (108,959 ) (53,199 ) Net Property and Equipment $ 1,282,440 $ 111,029

Notes Payable_Convertible Debt

Notes Payable/Convertible Debt (Tables)	9 Months Ended
	Oct. 31, 2020
Debt Disclosure [Abstract]
Schedule of Minimum lease payments	Years ending January 31, 2021 $ 5,953 January 31, 2022 24,738 January 31, 2023 26,295 January 31, 2024 27,948 January 31, 2025 26,361 January 31, 2026 16,202 Total $ 127,497

Intangible Assets (Tables)

Intangible Assets (Tables)	9 Months Ended
	Oct. 31, 2020
Goodwill and Intangible Assets Disclosure [Abstract]
Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization	October 31, January 31, 2020 2020 Customer base $ 136,500 $ 136,500 Intellectual property 234,200 234,200 Total 370,700 370,700 Less: Accumulated amortization (83,802 ) (56,000 ) Net Intangible Assets $ 286,898 $ 314,700
Schedule of estimated amortization	Total Year Ended January 31, 2021 $ 9,267 2022 37,070 2023 37,070 2024 37,070 2025 and thereafter 166,421 $ 286,898

Derivative Liabilities (Tables)

Derivative Liabilities (Tables)	9 Months Ended
	Oct. 31, 2020
Derivative Instruments and Hedging Activities Disclosure [Abstract]
Schedule reconciliation of Derivative Liabilities	October 31, Balance at the beginning of the period $ 928,774 Derivative liability warrants reclassed to equity (906,678 ) Change in value of embedded conversion option (22,096 ) $ -

Warrants (Tables)

Warrants (Tables)	9 Months Ended
	Oct. 31, 2020
Warrants [Abstract]
Schedule of warrants	Exercise Remaining Intrinsic Shares Price Life Value Outstanding, January 31, 2020 70,000 $ 18.93 1.53 years $ - Granted 91,828 12.53 3.00 years - Expired/Cancelled (20,000 ) 14.00 - - Exercised - - - - Outstanding-period ending October 31, 2020 141,828 $ 11.99 2.16 years $ 285,000 Exercisable - period ending October 31, 2020 141,828 $ 11.99 2.16 years $ 285,000
Schedule of additional warrants outstanding	Range of Exercise Prices Number Outstanding Remaining Contractual Life(Years) Exercise Price for Shares Outstanding Number Exercisable Exercise Price for Shares Exercisable Intrinsic Value $ 11.00 95,000 2.25 $ 11.00 95,000 $ 11.00 $ 237,500 $ 14.00 46,828 2.75 $ 14.00 46,828 $ 14.00 $ -

Organization and Description _2

Organization and Description of Business (Details) - USD ($)	Aug. 01, 2018	Aug. 31, 2020	Jun. 25, 2019	Jul. 27, 2018	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Accounting Policies [Abstract]
Description of acquired	the Company acquired 4P Therapeutics LLC (“4P Therapeutics”) for $2,250,000, consisting of 62,500 shares of common stock, valued at $1,850,000, and $400,000, and a royalty payable to the former owner of 4P Therapeutics, of 6% on all revenue generated by the Company from the abuse deterrent intellectual property that had been developed by 4P Therapeutics. The former owner of 4P Therapeutics has been a director of the Company since April 2018, when the Company entered into the agreement to acquire 4P Therapeutics.
Acquired Percentage		100.00%
Purchase price		$ 6,000,000		$ 2,500,000	$ 6,000,000		$ 6,000,000
Issuance of shares (in Shares)		608,519		1,250,000
Principal amount		$ 1,500,000
Capital raise of no less		4,000,000
Public offering less		$ 4,000,000
Reverse stock split, description			On June 25, 2019, the Company effected one-for-four reverse split, pursuant to which each share of common stock became and was converted into 0.25 share of common stock.
Revenue					391,797	$ 82,567	595,611	$ 351,070
Cost of revenues					$ 228,772	$ 106,126	420,648	$ 422,879
Loss from operations							$ 414,261

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Details) - USD ($)	9 Months Ended
	Oct. 31, 2020	Aug. 31, 2020	Jan. 31, 2020	Oct. 31, 2019
Summary of Significant Accounting Policies (Details) [Line Items]
Property plant and equipment, description	Expenditures for minor repairs, maintenance and replacement parts which do not increase the useful lives of the assets are charged to expense as incurred. The lives over which the fixed assets are depreciated range from 3 to 5 years as follows:
Goodwill	$ 8,187,196	$ 6,467,961
Common stock equivalents outstanding (in Shares)	141,830			133,214
Derivative Liability	$ 0		$ 928,774
Intangible Assets [Member]
Summary of Significant Accounting Policies (Details) [Line Items]
Amortized estimated useful lives	10 years

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details) - Schedule of disaggregation of revenues - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Schedule of disaggregation of revenues [Abstract]
Sale of goods	$ 347,216		$ 467,986	$ 142,450
Services	44,581	82,567	127,625	208,620
Total	$ 391,797	$ 82,567	$ 595,611	$ 351,070

Summary of Significant Accoun_5

Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographic location - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographic location [Line Items]
Total	$ 391,797	$ 82,567	$ 595,611	$ 351,070
United States [Member]
Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographic location [Line Items]
Total	155,083	82,567	238,127	208,620
Non-United States [Member]
Summary of Significant Accounting Policies (Details) - Schedule of revenue by geographic location [Line Items]
Total	$ 236,714		$ 357,484	$ 142,450

Summary of Significant Accoun_6

Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment	9 Months Ended
	Oct. 31, 2020
Lab equipment [Member] | Minimum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]
Property plant and equipment, Usefull life	5 years
Lab equipment [Member] | Maximum [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]
Property plant and equipment, Usefull life	10 years
Furniture, fixtures and equipment [Member]
Summary of Significant Accounting Policies (Details) - Schedule of property plant and equipment [Line Items]
Property plant and equipment, Usefull life	3 years

Acquisition of Business (Detail

Acquisition of Business (Details) - USD ($)	1 Months Ended	9 Months Ended
	Aug. 31, 2020	Oct. 31, 2020
Business Combinations [Abstract]
Acquired of membership interests	100.00%
Acquired common stock value	$ 6,000,000
Acquired common stock, shares (in Shares)	608,519
Principal amount	$ 1,500,000
Capital raise of no less	4,000,000
Public offering less	$ 4,000,000
Annual meeting of shareholders, term		1 year
Net revenues		$ 186,917
Net profit		$ 30,416

Acquisition of Business (Deta_2

Acquisition of Business (Details) - Schedule of net assets acquired	9 Months Ended
	Oct. 31, 2020USD ($)
Schedule of net assets acquired [Abstract]
Common stock issued	$ 6,000,000
Note payable issued	1,500,000
Total	7,500,000
Cash	66,994
Accounts receivable	1,761
Inventory	42,613
Equipment	1,227,171
Accounts payable and accrued expenses	(10,577)
Deferred revenue	(26,851)
Debt	(269,072)
Net assets acquired	1,032,039
Goodwill (provisional)	6,467,961
Total	$ 7,500,000

Acquisition of Business (Deta_3

Acquisition of Business (Details) - Schedule of unaudited pro forma condensed financial information - USD ($)	3 Months Ended		9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019	Oct. 31, 2020	Oct. 31, 2019
Schedule of unaudited pro forma condensed financial information [Abstract]
Net revenue	$ 391,797	$ 82,567	$ 595,611	$ 351,070
Net revenue, Proforma			2,167,208	2,362,122
Net loss	$ (42,569)	$ (753,274)	(680,632)	(1,777,192)
Net loss, Proforma			$ (609,741)	$ (1,540,409)
Loss per common share - basic and diluted (in Dollars per share)	$ (0.01)	$ (0.14)	$ (0.12)	$ (0.33)
Loss per common share - basic and diluted, Proforma (in Dollars per share)			$ (0.10)	$ (0.26)

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Property, Plant and Equipment [Abstract]
Depreciation expense	$ 55,760	$ 26,338

Property and Equipment (Detai_2

Property and Equipment (Details) - Schedule of property and equipment - USD ($)	Oct. 31, 2020	Jan. 31, 2020
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 1,391,399	$ 164,228
Less: Accumulated depreciation	(108,959)	(53,199)
Net Property and Equipment	1,282,440	111,029
Lab Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	1,371,756	144,585
Furniture, fixtures and equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment, gross	$ 19,643	$ 19,643

Notes Payable_Convertible Deb_2

Notes Payable/Convertible Debt (Details) - USD ($)	1 Months Ended						9 Months Ended	12 Months Ended
	Aug. 31, 2020	Jul. 31, 2020	Mar. 31, 2020	Mar. 27, 2020	Mar. 21, 2020	Oct. 30, 2019	Oct. 31, 2020	Jan. 31, 2020	Mar. 25, 2020
Notes Payable/Convertible Debt (Details) [Line Items]
Notes payable, description					the Coronavirus Aid Relief and Economic Security Act (“CARES ACT” was enacted. The CARES ACT established the Paycheck Protection Program (“PPP”) which funds small businesses through federally guaranteed loans. Under the PPP, companies are eligible for forgiveness of principal and interest if the proceeds are used for eligible payroll costs, rent and utility costs. On June 17, 2020, the Company’s subsidiary, 4P Therapeutics, was advanced $34,870 under the PPP, all of which was outstanding as of October 31, 2020. The note matures June 17, 2022 and accrues interest at 0.98% per year.
Loan amount								$ 215,000
Additional loan		$ 100,000	$ 60,000
Total loan			$ 275,000
Conversion stock issued (in Shares)				25,000
Convertible debt amount				$ 275,000
Loss on extinguishment of debt				$ 12,500
Line of credit amount							$ 160,000
Line of credit, term							October 16, 2029
Interest rate, percentage							5.00%
Payments of principal interest							$ 1,697
Balance due							133,549
Convertible notes payable current							$ 19,000
Lease of description							The leases mature in 2025 and 2026.
Borrowing rate, percentage							5.00%
Repaid amount							$ 44,262
Related party payable, description	the Company issued to Pocono Coated Products LLC a promissory note in the amount of $1,500,000 with interest accruing at an annual rate of 0.17%, due on August 28, 2021 or immediately following the earlier of a capital raise of no less than $4,000,000 and/or a public offering of no less than $4,000,000. Pocono Coated Products LLC, a relate party, is a shareholder of the Company.
Convertible notes payable, description						the Company entered into a securities purchase agreement with two investors pursuant to which the Company issued to the investors (i) 6% one-year convertible promissory notes in the principal amount of $270,000 and (ii) three-year warrant to purchase 50,000 shares of common stock at an exercise price equal to the lesser of (i) $20.90 or (ii) if the Company completes a public offering, 110% of the initial public offering price of the common stock in the public offering. The loans contained an original issue discount of $20,000 resulting in gross proceeds from this financing of $250,000.
Description of convertible notes						the lesser of (i) the per share price of our common stock offered in a public offering or (ii) the variable conversion price, which is defined as 70% of the lowest trading price of the common stock during the 20 trading days preceding the date of conversion. The conversion price and the percentage of the trading price is subject to downward adjustment in the event the Company fails to comply with the obligations under the notes. The Company has the right to prepay the notes during the 180 days following the issuance of the notes at a premium of 115% of the outstanding principal and interest during the 60 days following the date of issuance of the note, which percentage increases to 125% during the remainder of the 180-day period. The Company is required to pay the notes one business day after the closing of the first to occur of (a) the next public offering of the Company’s securities or (b) the next private placement of the Company’s equity or debt securities in which the Borrower received net proceeds of at least $1.0 million, (c) issuance of securities pursuant to an equity line of credit or (d) a financing with a bank or other institutional lender.
Fair value of conversion price							128,870
Fair value of the warrants							888,789
Debt discount							270,000	67,500
initial derivative expense							767,650
Discount remaining amount								202,500
Principal amount									$ 270,000
Prepayment fee							69,131
Accrued interest							345,565
Derivative liability								928,774
Interest expenses including debt discount amount							205,900
Officers [Member]
Notes Payable/Convertible Debt (Details) [Line Items]
Balance due							11,567
Advanced amount								$ 29,067
Expenses amount							$ 3,628

Notes Payable_Convertible Deb_3

Notes Payable/Convertible Debt (Details) - Schedule of Minimum lease payments	Oct. 31, 2020USD ($)
Schedule of Minimum lease payments [Abstract]
Years ending January 31, 2021	$ 5,953
January 31, 2022	24,738
January 31, 2023	26,295
January 31, 2024	27,948
January 31, 2025	26,361
January 31, 2026	16,202
Total	$ 127,497

Intangible Assets (Details)

Intangible Assets (Details) - USD ($)	9 Months Ended
	Oct. 31, 2020	Oct. 31, 2019
Goodwill and Intangible Assets Disclosure [Abstract]
Amortized over period	10 years
Amortization expense	$ 27,802	$ 27,802

Intangible Assets (Details) - S

Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization - USD ($)	Oct. 31, 2020	Jan. 31, 2020
Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]
Total	$ 370,700	$ 370,700
Less: Accumulated amortization	(83,802)	(56,000)
Net Intangible Assets	286,898	314,700
Customer base [Member]
Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]
Total	136,500	136,500
Intellectual property [Member]
Intangible Assets (Details) - Schedule of intangible assets consisted of intellectual property, customer base and trademarks, net of amortization [Line Items]
Total	$ 234,200	$ 234,200

Intangible Assets (Details) -_2

Intangible Assets (Details) - Schedule of estimated amortization	Jan. 31, 2020USD ($)
Schedule of estimated amortization [Abstract]
2021	$ 9,267
2022	37,070
2023	37,070
2024	37,070
2025 and thereafter	166,421
Total amortization	$ 286,898

Derivative Liabilities (Details

Derivative Liabilities (Details)	9 Months Ended	12 Months Ended
	Oct. 31, 2020	Jan. 31, 2020
Derivative Liabilities (Details) [Line Items]
Expected volatility	158.30%
Risk-free interest rate	1.58%
Expected term	1 year
Re-Valuation [Member]
Derivative Liabilities (Details) [Line Items]
Expected volatility		184.40%
Risk-free interest rate		1.43%

Derivative Liabilities (Detai_2

Derivative Liabilities (Details) - Schedule reconciliation of derivative liabilities - Level 3 [Member]	9 Months Ended
	Oct. 31, 2020USD ($)
Fair Value, Net Derivative Asset (Liability) Measured on Recurring Basis, Unobservable Input Reconciliation [Line Items]
Balance at the beginning of the period	$ 928,774
Derivative liability warrants reclassed to equity	(906,678)
Change in value of embedded conversion option	(22,096)
Balance at the end of the period

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($)	1 Months Ended		6 Months Ended	9 Months Ended
	Jan. 31, 2020	Feb. 19, 2019	Jul. 31, 2019	Oct. 31, 2020
Related Party Transactions [Abstract]
Cash received				$ 400,000
Common stock issued (in Shares)				250,000
Common stock value				$ 1,850,000
Stock, description		the Company granted an executive officer an option to purchased 25,000 shares of the Company’s common stock at an exercise price equal to 75% of the market price on the date the Company receives notice of exercise.
Fair value of warrant expense			$ 252,700
Warrant, description				The warrant expired unexercised on May 19, 2019.
Related party transaction, description	the Company owed its chief financial officer and chief operating officer $29,067 from advances made to the Company. During the nine months ended October 31, 2020, the Company’s chief financial officer paid expenses of $3,628 on behalf the Company, the Company’s chief executive officer and chief operating officer advanced the Company $11,567 and the officers were repaid $35,195. As of October 31, 2020, the Company owed the officers $-0-.			the Company a net amount of $39,777, comprised of $69,855 of trade accounts receivable and $30,078 in Accounts payable and Accrued expenses on the balance sheet. The PCP Segment was a former vendor of Nutriband and prior to September 1, 2020, these expenses have not been eliminated as intercompany expenses, like they are after the acquisition date. These expenses amounted to $173,310.
Revenue transactions				$ 121,563
Purchase of materials				70,230
Expenses paid				9,324
Finance payments				$ 3,307

Stockholders' Equity (Details)

Stockholders' Equity (Details) - USD ($)	Mar. 22, 2020	Jun. 20, 2019	Aug. 31, 2020	Jun. 30, 2020	Mar. 31, 2020	May 24, 2019	Jul. 27, 2018	Oct. 31, 2020	Oct. 31, 2020	Jan. 31, 2020	Jan. 27, 2020	Jun. 25, 2019	Jan. 15, 2016
Stockholders' Equity (Details) [Line Items]
Preferred stock, shares authorized								10,000,000	10,000,000	10,000,000			10,000,000
Preferred stock, par value (in Dollars per share)								$ 0.001	$ 0.001	$ 0.001			$ 0.001
Preferred stock, shares designated (in Dollars)		$ 2,500,000				$ 2,500,000
Private Placement	46,828
Warrant to purchase of common stock (in Dollars per share)	$ 11
Exercise price of warrants (in Dollars per share)	$ 14
Received proceeds of common stock (in Dollars)									$ 515,108
Common stock of, description				the Company issued 5,000 shares to a consultant for services rendered to the Company. The fair value of the common stock at the date of issuance was $50,000, which is included in selling and general administrative expense for the nine months ended October 31, 2020.	In March 2020, a minority shareholder who had previously made loans of $215,000, made an additional loan to the Company in the amount of $60,000, increasing the loans to shareholder to $275,000. On March 27, 2020, the Company issued 25,000 shares of common stock upon reaching a settlement with the noteholder to convert the notes in the principal amount of $275,000. The transaction resulted in a loss on extinguishment of $12,500.
Issued of shares			608,519				1,250,000
Common stock, value (in Dollars)			$ 6,000,000				$ 2,500,000	$ 6,000,000	$ 6,000,000
Principal amount (in Dollars)			$ 1,500,000
Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Debt Instrument, Convertible, Conversion Price (in Dollars per share)												$ 0.25
Issuance shares of common stock, shares									46,828
Warrant to purchase of common stock									46,828
Issued of shares								608,581	608,581
Common stock, value (in Dollars)								$ 609	$ 609
Minimum [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Increase decreased in authorized common stock											25,000,000	100,000,000
Maximum [Member] | Common Stock [Member]
Stockholders' Equity (Details) [Line Items]
Increase decreased in authorized common stock											250,000,000	25,000,000

Warrants (Details)

Warrants (Details) - USD ($)	1 Months Ended	9 Months Ended
	Mar. 31, 2020	Oct. 31, 2020
Warrants (Textual)
Purchase of warrants shares		50,000
Exercise price		$ 20.90
Initial public offering price, percentage		110.00%
Derivative liability for warrant		$ 906,678
Warrants and rights outstanding, maturity date	Apr. 30, 2023
IPO [Member]
Warrants (Textual)
Purchase of warrants shares		95,000
Per share		$ 11
Private Placement [Member]
Warrants (Textual)
Purchase of warrants shares	46,828
Per share	$ 14

Warrants (Details) - Schedule o

Warrants (Details) - Schedule of warrants - Warrants [Member]	9 Months Ended
	Oct. 31, 2020USD ($)$ / sharesshares
Class of Warrant or Right [Line Items]
Shares, Outstanding, Beginning Balance | shares	70,000
Exercise Price, Outstanding, Beginning Balance | $ / shares	$ 18.93
Remaining Life, Outstanding, Beginning Balance	1 year 193 days
Intrinsic Value, Outstanding, Beginning Balance | $
Shares, Granted | shares	91,828
Exercise Price, Granted | $ / shares	$ 12.53
Remaining Life, Granted	3 years
Intrinsic Value, Granted | $
Shares, Expired/Cancelled | shares	(20,000)
Exercise Price, Expired/Cancelled | $ / shares	$ 14
Remaining Life, Expired/Cancelled
Intrinsic Value, Expired/Cancelled | $
Shares, Exercised | shares
Exercise Price, Exercised | $ / shares
Remaining Life, Exercised
Intrinsic Value, Exercised | $
Shares, Outstanding, Ending Balance | shares	141,828
Exercise Price, Outstanding, Ending Balance | $ / shares	$ 11.99
Remaining Life, Outstanding, Ending Balance	2 years 58 days
Intrinsic Value, Outstanding, Ending Balance | $	$ 285,000
Shares, Exercisable | shares	141,828
Exercise Price, Exercisable | $ / shares	$ 11.99
Remaining Life, Exercisable	2 years 58 days
Intrinsic Value, Exercisable | $	$ 285,000

Warrants (Details) - Schedule_2

Warrants (Details) - Schedule of additional warrants outstanding	12 Months Ended
	Dec. 31, 2020USD ($)$ / sharesshares
Warrants (Details) - Schedule of additional warrants outstanding [Line Items]
Range of Exercise Prices	14
Number Outstanding	46,828
Remaining Contractual Life(Years)	2 years 9 months
Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares	$ 14
Number Exercisable	46,828
Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares	$ 14
Intrinsic value (in Dollars) | $
Warrants [Member]
Warrants (Details) - Schedule of additional warrants outstanding [Line Items]
Range of Exercise Prices	11
Number Outstanding	95,000
Remaining Contractual Life(Years)	2 years 3 months
Exercise Price for Shares Outstanding (in Dollars per share) | $ / shares	$ 11
Number Exercisable	95,000
Exercise Price for Shares Exercisable (in Dollars per share) | $ / shares	$ 11
Intrinsic value (in Dollars) | $	$ 237,500

Contingencies (Details)

Contingencies (Details) - USD ($)	1 Months Ended					3 Months Ended	9 Months Ended	12 Months Ended
	Aug. 31, 2020	Apr. 29, 2019	Jan. 31, 2019	Jul. 27, 2018	May 16, 2018	Oct. 31, 2020	Oct. 31, 2020	Jan. 31, 2020	Feb. 19, 2019
Contingencies (Details) [Line Items]
Acquired advanced shares of common stock (in Shares)	608,519			1,250,000
Acquired advanced shares of common stock value	$ 6,000,000			$ 2,500,000		$ 6,000,000	$ 6,000,000
Compensation annual rate								$ 170,000
Public or private financing								2,500,000
Defendants [Member]
Contingencies (Details) [Line Items]
Shares cancelled (in Shares)			50,000
Chief Executive Officer [Member]
Contingencies (Details) [Line Items]
Compensation annual rate								$ 42,000
President [Member]
Contingencies (Details) [Line Items]
Annual salary					$ 60,000
Chief Scientific Officer [Member]
Contingencies (Details) [Line Items]
Compensation annual rate									$ 60,000
Health Brans, Inc. [Member]
Contingencies (Details) [Line Items]
Acquired advanced shares of common stock (in Shares)		1,250,000